Compare AbCellera Biologics Inc (ABCL) vs Standard Lithium Ltd (SLI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Standard Lithium Ltd — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Standard Lithium Ltd trades at $2.47 (market cap $592.60M). The key difference: AbCellera Biologics Inc is far larger — about 4× Standard Lithium Ltd's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals.
| ABCL | SLI | |
|---|---|---|
Market Cap | $2.35B | $592.60M |
Sector | Health | Basic Materials |
52-Week High | $8.12 | $5.65 |
52-Week Low | $2.78 | $2.29 |
Enterprise Value | $1.99B | $451.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Standard Lithium (SLI) trades at $2.68, down 1.47% on the day, with a bearish technical signal from moving averages despite some bullish oscillators. The company reported a net loss of $48.40 million in 2025, with negative ROE and ROA, but maintains a P/B ratio of 1.8. Recent news highlights progress on its South West Arkansas lithium project, including a $225 million DOE grant and key construction contracts, positioning it for a final investment decision in 2026.
The investment case hinges on successful project execution and lithium market dynamics, with 100% analyst buy ratings signaling strong growth potential. Key risks include persistent negative cash flow from operations, high capital expenditures, and execution delays. Upside depends on timely project completion and favorable lithium pricing, while downside risks involve funding gaps and operational setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →
